Think in terms of their first drug application, Provenge being approved very soon by the FDA because it dramatically helps late stage PC patients with almost no side effects.

Soon after, it will be discovered that if it does so much good in late stage PC, imagine how much good it can do if applied in the early stages. Everyone with PC cancer (including me) will want this drug, not just the late stage guys. This is an area not yet explored by testing, but the results are easy to predict. The market will expand exponentially, and so will revenues and share prices. None of this is included in today's projections of value.

Now think in terms of similar technology being applied to breast cancer and Neuvenge being approved in 2-3 years.

If that works (and indications are that it will), then the same technology might be used successfully for several other cancers. Whether tested or not, since it has virtually NO side effects, anyone with cancer is going to want it, and doctors will prescribe it "off shelf" for many cancers other than PC.

The revenues and price per share will explode up from higher highs.

This stock may turn out to be the biggest gainer of the century, as DNDN technology may be the magic bullet that fights many cancers successfully. Whether it is or not, it will likely have sales reflecting this exalted status, and the pps will soar accordingly.

If you accept this logic (and I obviously do) then valuation potential is simply stratospheric, in my humble opinion.

Ask any medical expert. Ask a doctor. But whatever you do, don't sell a share. The major funds certainly aren't selling, but clearly are accumulating shares for the inevitable rise.